House bill passes FDA funding fees but conflicts with Senate bill

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

House bill passes FDA funding fees but conflicts with Senate bill

Home/Policies & Legislation | Posted 15/07/2022 0 Post your comment

In the Unites States (US), the House of Representatives voted to pass legislation to reauthorize the fees that help fund the US Food and Drug Administration (FDA). However, there are some conflicts between the House and parallel Senate bill that need to be overcome before either can be passed.

On 8 June 2022, House members voted to pass a measure (H.R. 7667) that will set a US$1.15 billion base fee amount for human prescription drugmakers for the fiscal year of 2023. In addition, as part of the package, FDA’s accelerated approval pathway is set to be updated.

The current fee agreement is due to expire on 30 September 2022 and this new package is set to reauthorize the user fees FDA gets from the drug and medical device industries between 2023–2027. These FDA user fees make up approximately half of FDA’s budget.

H.R. 7667 and the parallel US Senate bill do have some substantial differences, for example, the House bill includes provisions for paediatric cancer research, to speed up the approval of generic drugs, and to improve diversity in clinical trials, which are not present in the Senate version.

The House measure is also set to give FDA the authority to remove any drugs from the market that obtained accelerated approval if they fail to show a clinical benefit. It will also allow the agency to require drug and device companies to submit diversity action plans for their clinical trials.

In contrast, the Senate proposal is set to revamp how FDA regulates diagnostic tests, and will require opioids to be dispensed with safe, in-home disposal systems.

For the parallel bills to be passed by President Biden, they must first become more confluent.

Biosimilar User Fee Act reauthorization

FDA to hold public meeting on its user fee programmes

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.